Sector consensus Neurizon Therapeutics Limited

Equities

Delayed Australian S.E. Other stock markets 09:58:28 20/05/2026 am IST			5-day change	1st Jan Change
0.0660 ^AUD	-2.94%		-4.35%	-22.35%

13/05	Neurizon Therapeutics receives ethics approval for Phase 1 Nuz-001 oral liquid formulation study	RE
13/05	Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Average Target P.	Objective/dr gap	Nbr of analysts
NEURIZON THERAPEUTICS LIMITED	-	-	0.28	+300%	1
ELI LILLY AND COMPANY			1,210	+22.46%	29
JOHNSON & JOHNSON			252.96	+10.5%	24
ABBVIE INC.			252.9	+20.77%	29
ROCHE HOLDING AG			360.76	+12.14%	17
ASTRAZENECA PLC			221.62	+20.68%	21
NOVARTIS AG			155.31	+4.18%	21
MERCK & CO., INC.			129.74	+15.26%	27
NOVO NORDISK A/S			307.99	+7.69%	23
AMGEN INC.			352.23	+8.58%	30
GILEAD SCIENCES, INC.			157.96	+21.82%	28
PFIZER INC.			29.19	+15.23%	27
BRISTOL-MYERS SQUIBB COMPANY			62.96	+9.86%	25
VERTEX PHARMACEUTICALS INCORPORATED			549.29	+25.82%	28
SANOFI			97.1	+30.61%	23
GSK PLC			20.32	+8.29%	20
CHUGAI PHARMACEUTICAL CO., LTD.			10,096.67	+28.05%	15
TAKEDA PHARMACEUTICAL COMPANY LIMITED			6,123.53	+16.66%	15
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD			82.08	+56.55%	17
BAYER AG			48.58	+28.41%	19
Average			1,025.57	+33.18%	22
Weighted average by Cap.			682.65	+16.84%	25